Evolution of the randomized clinical trial in the era of precision oncology
26 Mar, 2021 | 08:35h | UTCEvolution of the Randomized Clinical Trial in the Era of Precision Oncology – JAMA Oncology
Commentary on Twitter
Food for thoughts: randomized clinical trials in the era of precision oncology
➡️PFS, not OS predominant endpoint
➡️Modest median survival gains
➡️Almost all industry funded
➡️Substantial increase in use of professional medical writers#radonchttps://t.co/k92MEs1eWR— Matthias Guckenberger (@Mat_Guc) March 25, 2021